Top Forbes SHOOK advisors pledge $1.5M to fund kidney cancer treatment at Sloan Kettering Cancer Center in New York ...

This case is part of a larger wave of litigation involving PFAS contamination against chemical manufacturers over the health ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated ...

Cancer treatment, especially at later stages ... Similarly, Justin, a Stage IV kidney cancer patient, experienced ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

Defective VHL protein is also present in most cases of advanced clear cell renal cell carcinoma (RCC), so a recommendation for belzutifan was issued to also cover this condition. The drug is indicated ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...